◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Molecular Partners AG (MOLN) Financial History

Name: Molecular Partners AG (MOLN) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-08-16

Molecular Partners AG (MOLN) operates in the Biotechnology industry and is headquartered in Schlieren, Switzerland with about 134 employees. Its market capitalization is roughly CHF 126 million. In the fiscal year ended 2025-12-31, MOLN reported CHF 0M in revenue and (CHF 62M) in net income.

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland.

Interactive charts & full statements →

MOLN Revenue & Earnings History — Annual Income Statement

Income statement	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total Revenue	CHF 0M	CHF 5M	CHF 7M	CHF 190M	—
Operating Income (EBIT)	(CHF 55M)	(CHF 61M)	(CHF 61M)	CHF 117M	—
Net Income	(CHF 62M)	(CHF 54M)	(CHF 62M)	CHF 118M	—

CHF; CHFM / CHFB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

MOLN Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31
Total Revenue	CHF 0M	CHF 0M	CHF 0M	CHF 0M	CHF 0M
Operating Income (EBIT)	(CHF 13M)	(CHF 13M)	(CHF 12M)	(CHF 15M)	(CHF 16M)
Net Income	(CHF 13M)	(CHF 13M)	(CHF 12M)	(CHF 20M)	(CHF 17M)

CHF; CHFM / CHFB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

MOLN Free Cash Flow History

MOLN Balance Sheet History

Balance sheet	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total Assets	CHF 102M	CHF 158M	CHF 198M	CHF 262M	—
Total Liabilities	CHF 22M	CHF 17M	CHF 22M	CHF 27M	—

CHF; CHFM / CHFB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive MOLN viewer.

Other Companies in Biotechnology

MIST · Milestone Pharmaceuticals Inc. — $137 million
HURA · TuHURA Biosciences, Inc. — $136 million
PMN · ProMIS Neurosciences, Inc. — $133 million
SPRB · Spruce Biosciences, Inc. — $128 million
TLSA · Tiziana Life Sciences Ltd — $126 million
VTVT · vTv Therapeutics Inc. — $122 million
SEER · Seer, Inc. — $121 million
ENGN · enGene Therapeutics Inc. — $121 million

← MOH All “M” companies MOLY →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.